Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sean C Blackwell, Erin M Sullivan, Allison A Petrilla, Xian Shen, Kathleen A Troeger & James D Byrne. (2017) Utilization of fetal fibronectin testing and pregnancy outcomes among women with symptoms of preterm labor. ClinicoEconomics and Outcomes Research 9, pages 585-594.
Read now
Read now
June Felice Johnson, Rahul Parsa & Robert Bailey. (2017) Real world clinical outcomes and patient characteristics for canagliflozin treated patients in a specialty diabetes clinic. Current Medical Research and Opinion 33:1, pages 77-84.
Read now
Read now
Patrick Lefebvre, Dominic Pilon, Marie-Noëlle Robitaille, Marie-Hélène Lafeuille, Wing Chow, Michael Pfeifer & Mei Sheng Duh. (2016) Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin—an electronic health-record-based study. Current Medical Research and Opinion 32:6, pages 1151-1159.
Read now
Read now
Articles from other publishers (8)
Manuel A. Gargallo-Fernández, Alba Galdón Sanz-Pastor, Teresa Antón-Bravo, Miguel Brito-Sanfiel, Jaime Wong-Cruz & Juan J. Gorgojo-Martínez. (2021) Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study. Diabetology 2:3, pages 165-175.
Crossref
Crossref
Carol H. Wysham, Patrick Lefebvre, Dominic Pilon, Marie-Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Michael Pfeifer, Mei Sheng Duh & Mike Ingham. (2019) An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. Journal of Diabetes and its Complications 33:2, pages 140-147.
Crossref
Crossref
Carol H. Wysham, Dominic Pilon, Mike Ingham, Marie -Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Michael Pfeifer & Patrick Lefebvre. (2018) Hba1C Control And Cost-Effectiveness in Patients With Type 2 Diabetes Mellitus Initiated On Canagliflozin or A Glucagon-Like Peptide 1 Receptor Agonist in A Real-World Setting. Endocrine Practice 24:3, pages 273-288.
Crossref
Crossref
Ruth E. BrownNikhil GuptaRonnie Aronson. (2017) Effect of Dapagliflozin on Glycemic Control, Weight, and Blood Pressure in Patients with Type 2 Diabetes Attending a Specialist Endocrinology Practice in Canada: A Retrospective Cohort Analysis. Diabetes Technology & Therapeutics 19:11, pages 685-691.
Crossref
Crossref
June Felice Johnson, Rahul Parsa & Robert A. Bailey. (2017) Real-world Clinical Outcomes Among Patients With Type 2 Diabetes Receiving Canagliflozin at a Specialty Diabetes Clinic: Subgroup Analysis by Baseline HbA 1c and Age. Clinical Therapeutics 39:6, pages 1123-1131.
Crossref
Crossref
Erin K. Buysman, Amy Anderson, Shaffeeulah Bacchus & Mike Ingham. (2017) Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin. Advances in Therapy 34:4, pages 937-953.
Crossref
Crossref
Wing Chow, Gavin Miyasato, Fotios K. Kokkotos, Robert A. Bailey, Erin K. Buysman & Henry J. Henk. (2016) Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus—A Multi-Database Synthesis. Clinical Therapeutics 38:9, pages 2071-2082.
Crossref
Crossref
Robert A. Bailey, Phil Schwab, Yihua Xu, Margaret Pasquale & Andrew Renda. (2016) Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice. Clinical Therapeutics 38:9, pages 2046-2057.e2.
Crossref
Crossref